Naltrexone is one of the medications approved in the United States for alcohol use disorder. It may help reduce the urge to drink, but suitability depends on an individual medical assessment. The most useful discussion is not simply whether a program offers it. Ask why it might fit your goals, what safety issues need review, and how its effect will be assessed within continuing care.

The NIAAA treatment overview describes naltrexone as available in pill and injectable forms. This guide explains questions to take to a qualified prescriber. It does not provide a starting schedule, a dose, or instructions for switching medicines. Those decisions depend on the formulation, current health, substance use, and the prescribing assessment.

Start with the intended benefit

Describe what you hope treatment will change. This might concern urges to drink, recurring heavy drinking, difficulty maintaining an agreed goal, or a return to drinking after earlier treatment. Tell the clinician what has already been tried and what made it difficult. A previous experience with medication is useful information, including whether it was available consistently and whether follow-up occurred.

Ask how naltrexone would fit with the goal you have agreed, rather than assuming that everyone receives the same plan. Clarify the expected benefit and its limits. A medication can help without eliminating every craving or solving every social and emotional problem associated with drinking. The review should assess a meaningful treatment outcome rather than rely on a promise of complete control.

Discuss what else belongs in care. The NIAAA questions for treatment programs encourage asking about evidence-based approaches and access to medication when appropriate. Behavioral treatment, practical support, and attention to other health concerns may each contribute. Ask the team to explain their roles instead of presenting medication and counseling as competing choices.

Make opioid history a central part of the assessment

Naltrexone blocks opioid effects. The current oral naltrexone labeling, checked October 18, 2026, identifies important restrictions related to opioid treatment, dependence, and withdrawal. Starting it in someone physically dependent on opioids can trigger severe withdrawal. Tell the prescriber about recent prescribed or nonprescribed opioid use, including treatment with methadone or buprenorphine.

Do not decide that an opioid is irrelevant because it was prescribed for pain or taken only occasionally. Bring its exact name, the instructions, actual use, and the last use as accurately as you can. If you are uncertain what a product contained, say so. The clinician needs the uncertainty as well as the known facts when deciding how to assess safety.

Do not stop established opioid treatment on your own to become eligible for naltrexone. Ask the responsible clinicians to consider the whole treatment plan. An alcohol treatment option should not be chosen in isolation from effective care for another condition. If naltrexone is unsuitable, discuss other alcohol treatment options rather than conclude that medication-based care is unavailable altogether.

Discuss pain treatment and planned procedures

Tell the prescriber about chronic pain, upcoming surgery, dental procedures, or another situation in which pain medication may be needed. Ask how the relevant clinicians will communicate. Because naltrexone affects opioid action, pain management requires an informed plan. Do not attempt to overcome its effect by taking extra opioid medicine or using nonprescribed opioids; this can be life-threatening.

Ask what information you should carry so emergency clinicians know you receive naltrexone. Include the formulation and the relevant administration history in the record agreed with the prescriber. A clear medication list is particularly helpful when care occurs outside the usual service. Do not rely on a family member being present or able to remember the details during an emergency.

If opioid exposure is a concern, ask about overdose prevention, access to an appropriate reversal medicine, and what others should know. Naltrexone should not be treated as a guarantee against overdose. The prescribing team should explain the risks relevant to starting, continuing, or stopping treatment and what requires emergency help. Follow that individualized plan rather than attempting to test the blockade.

Review physical and mental health before treatment

Explain liver and kidney conditions, previous medication reactions, pregnancy or breastfeeding considerations, and all current prescriptions and supplements. Ask what examination or tests are needed and who will review the results. Do not interpret a single laboratory value as an automatic decision for or against treatment; suitability needs the medical context and the current product information.

The oral label includes a warning about liver injury. Ask the clinician which symptoms to report promptly and what monitoring is appropriate for you. A past liver diagnosis deserves a specific discussion rather than reassurance based only on how well you feel. If a concerning symptom develops, contact the medical team according to the instructions you receive instead of waiting for a routine refill.

Also describe depression, anxiety, sleep problems, or thoughts of self-harm. These concerns should remain visible during alcohol treatment. Ask who will assess significant changes and how that care connects with the prescriber. Immediate danger of self-harm, severe confusion, collapse, or serious breathing difficulty requires emergency help; a medication follow-up appointment should not delay urgent assessment.

Compare formulations through practical needs

Pills and extended-release injections involve different routines and administration arrangements. Ask which formulation is being proposed and why. Consider appointment access, daily routines, privacy, prior difficulty taking medicines, and your preferences. The choice should include clinical suitability and the current labeling for that formulation, not simply the convenience of a program’s standard package.

If an injection is proposed, ask who administers it, where, and how follow-up or a missed appointment is handled. Request the formulation-specific information about adverse effects, including concerns at the injection site. If tablets are proposed, ask how to handle a missed dose or difficulty taking them. Obtain instructions from the prescriber or pharmacist; do not improvise a replacement schedule.

Clarify costs and access before a residential stay ends or a clinician changes. Are the medication, administration visit, and follow-up covered separately? Is a future appointment confirmed? A treatment choice can become difficult if the next service cannot provide the same formulation. Identifying that issue early allows the clinicians to plan continuity instead of leaving you to arrange a switch alone.

Distinguish ongoing treatment from withdrawal care

Naltrexone is not a substitute for assessment and management of alcohol withdrawal. MedlinePlus medication information makes this distinction. If reducing or stopping alcohol may cause withdrawal, discuss that risk with a clinician. Do not assume that taking an alcohol-use medication makes an unsupervised withdrawal attempt safe.

Our withdrawal assessment guide explains why previous episodes, current drinking, medical history, and other substances matter. The prescriber should clarify the timing of any ongoing medication in relation to the current clinical situation. A person leaving detox also needs clear instructions about which short-term medicines end and which treatments continue.

If different teams handle withdrawal and longer-term care, ask them to exchange the relevant record with appropriate consent. The medication review guide covers that handoff. The next clinician needs the actual treatment history and unresolved issues, not only a list of drug names copied without explanation from the discharge paperwork.

Ask the questions that prevent common misunderstandings

Naltrexone is different from naloxone, which is used to reverse an opioid overdose. Similar names do not make the products interchangeable. Ask the pharmacist to show you the exact product being prescribed and explain its purpose. Keep the name and formulation clear when talking with another clinician, particularly if both ongoing treatment and overdose prevention are part of your care.

It is also different from disulfiram, another alcohol treatment medication. The oral naltrexone label states that it does not produce a disulfiram-like alcohol reaction. That distinction is not permission to ignore alcohol-related risks or an agreed treatment goal. Ask the prescriber what the medication can and cannot change so that an inaccurate expectation does not guide your drinking decisions.

Finally, ask whether a proposed schedule follows the licensed product instructions or represents an individualized prescribing decision outside them. If the latter, request the rationale, supporting evidence, and monitoring plan in ordinary language. A treatment arrangement should be understandable without requiring you to evaluate online protocols or compare anecdotes about how someone else takes the medicine.

Decide how follow-up will judge benefit and burden

Agree what to record before the next review. Relevant information may include drinking patterns, urges, adverse effects, missed doses or appointments, and changes in daily functioning. Keep the record manageable enough to use honestly. A complicated tracking system that you abandon may provide less useful information than a short, consistent account of the outcomes you and the clinician selected.

Report renewed drinking or other substance use openly. Ask how the team will reassess treatment rather than guessing whether you should stop, increase, or restart medication. Also report when the medicine seems helpful but practical access is failing. Clinical effectiveness and the ability to obtain treatment are different issues, and both need a solution for the plan to continue.

Before leaving the prescribing conversation, understand the proposed formulation, safety assessment, current instructions, review date, and contact route. Ask what would lead to continuing, changing, or ending the treatment. A good decision about naltrexone is an ongoing process of informed prescribing and follow-up, connected to the wider alcohol treatment plan and your individual circumstances.

Sources and further reading

Found a detail that has changed? Tell the editorial team.